

Girard Armand
Form 3
March 06, 2019

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Girard Armand
(Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)
03/01/2019

3. Issuer Name and Ticker or Trading Symbol
GLYCOMIMETICS INC [GLYC]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

Director 10% Owner
 Officer Other
(give title below) (specify below)
SVP, Strategy & Corporate Dev

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

C/O GLYCOMIMETICS, INC.,Â 9708 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE,Â MDÂ 20850

(City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D)

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Date Exercisable Date Expiration Date

Title Amount or Number of

Edgar Filing: Girard Armand - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	Â (1)	04/20/2024	Common Stock	65,000	\$ 14.14	D	Â
Employee Stock Option (right to buy)	Â (2)	01/07/2025	Common Stock	5,516	\$ 7.15	D	Â
Employee Stock Option (right to buy)	Â (3)	01/06/2026	Common Stock	9,916	\$ 5.22	D	Â
Employee Stock Option (right to buy)	Â (4)	01/03/2027	Common Stock	30,000	\$ 6.33	D	Â
Employee Stock Option (right to buy)	Â (5)	01/09/2028	Common Stock	50,000	\$ 20.03	D	Â
Employee Stock Option (right to buy)	Â (6)	01/16/2029	Common Stock	65,000	\$ 10.59	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Girard Armand C/O GLYCOMIMETICS, INC. 9708 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	Â	Â	Â SVP, Strategy & Corporate Dev	Â

Signatures

/s/ Brian F. Leaf, 03/06/2019
Attorney-in-fact

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares underlying this option vested on April 21, 2015 and the remaining 75% of the shares vested in 36 equal monthly installments through April 21, 2018.
- (2) 25% of the shares underlying this option vested on January 8, 2016 and the remaining 75% of the shares vested in 36 equal monthly installments through January 8, 2019.
- (3) 25% of the shares underlying this option vested on January 7, 2017 and the remaining 75% of the shares will vest in 36 equal monthly installments through January 7, 2020.
- (4) 25% of the shares underlying this option vested on January 4, 2018 and the remaining 75% of the shares will vest in 36 equal monthly installments through January 4, 2021.
- (5) 25% of the shares underlying this option vested on January 10, 2019 and the remaining 75% of the shares will vest in 36 equal monthly installments through January 10, 2022.
- (6) 25% of the shares underlying this option will vest on January 17, 2020 and the remaining 75% of the shares will vest in 36 equal monthly installments through January 17, 2023.

Â

Remarks:

ExhibitÂ 24.1Â -Â PowerÂ ofÂ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.